Observational Clinical Research

Total Page:16

File Type:pdf, Size:1020Kb

Observational Clinical Research E REVIEW ARTICLE Clinical Research Methodology 2: Observational Clinical Research Daniel I. Sessler, MD, and Peter B. Imrey, PhD * † Case-control and cohort studies are invaluable research tools and provide the strongest fea- sible research designs for addressing some questions. Case-control studies usually involve retrospective data collection. Cohort studies can involve retrospective, ambidirectional, or prospective data collection. Observational studies are subject to errors attributable to selec- tion bias, confounding, measurement bias, and reverse causation—in addition to errors of chance. Confounding can be statistically controlled to the extent that potential factors are known and accurately measured, but, in practice, bias and unknown confounders usually remain additional potential sources of error, often of unknown magnitude and clinical impact. Causality—the most clinically useful relation between exposure and outcome—can rarely be defnitively determined from observational studies because intentional, controlled manipu- lations of exposures are not involved. In this article, we review several types of observa- tional clinical research: case series, comparative case-control and cohort studies, and hybrid designs in which case-control analyses are performed on selected members of cohorts. We also discuss the analytic issues that arise when groups to be compared in an observational study, such as patients receiving different therapies, are not comparable in other respects. (Anesth Analg 2015;121:1043–51) bservational clinical studies are attractive because Group, and the American Society of Anesthesiologists they are relatively inexpensive and, perhaps more Anesthesia Quality Institute. importantly, can be performed quickly if the required Recent retrospective perioperative studies include data O 1,2 data are already available. Epidemiologic and health ser- from tens-of-thousands to tens-of-millions of patients. vices investigators have used such approaches for decades. Large numbers per se limit research errors attributable But until recently, surgical and perioperative retrospective to chance, but do not prevent bias and confounding, and studies were too often “100-patient chart reviews,” which can exacerbate their effects by inducing overconfdence in rarely produced valid conclusions. Increasingly, though, biased results. But large samples do support more in depth the availability of electronic data and sophisticated statisti- and effective application of statistical techniques to com- cal techniques makes retrospective observational studies of pensate for known confounding factors than is possible surgical and perioperative practices a valuable tool. with small studies. Especially in anesthesia, there has been a revolution in Although analyses of observational data should gener- data quality and availability because of electronic anesthe- ally be considered exploratory rather than defnitive, they sia and hospital records. Consequently, some institutions are nonetheless often a relatively inexpensive and quick have large and dense (i.e., minute-to-minute) registries of way to evaluate the plausibility of hypotheses and build anesthesia care. Often they are linked to related hospital support for subsequent experimental studies. Done well, databases, such as those from clinical laboratories and retrospective analyses can provide good estimates of treat- blood banks, and to outcomes such as duration-of-hos- ment effect3–7 although they tend to underestimate harms pitalization and date-of-death. Billing codes also provide associated with interventions.8 Excellent guidelines have valuable information about diagnoses and procedures been published to encourage uniform and complete report- although the intricacies and requirements of reimburse- ing of observational studies, including full acknowledge- ment mechanisms, and of administrative record systems ment of limitations.9,10 more generally, can sometimes distort clinical realities. To glean the most information from such registries, there CASE SERIES are now several national registries that pool data from A case series—a description of what happened to a series of various institutions, notably the National Surgical Quality patients with a particular diagnosis, perhaps treated with a Improvement Project, Multicenter Perioperative Outcomes particular strategy—is certainly an improvement over anec- dotal experience and case reports because compiled data From the Department of Outcomes Research, Anesthesiology Institute, from a group are less likely to be idiosyncratic than results Cleveland Clinic, Cleveland, Ohio; and Department of Quantitative Health from 1 or a few individuals. There are many examples in Sciences, Lerner* Research Institute, Cleveland Clinic, Cleveland, Ohio. which case series, and even case reports, have provided crit- † Accepted for publication May 1, 2015. ical advances.9 Malignant hyperthermia, for example, was Funding: Supported by internal sources. initially reported as a case series and, because it is so rare, The authors declare no conficts of interest. has never been subject to randomized trial.10,11 Address correspondence to Daniel I. Sessler, MD, Department of Outcomes In a typical case series, physicians might report that 79 of Research, Anesthesiology Institute, Cleveland Clinic, 9500 Euclid Ave./P77, Cleveland, OH 44195. Address e-mail to [email protected]; website: www.OR.org. their patients given a particular treatment for heart failure Copyright © 2015 International Anesthesia Research Society had a median survival of 37 months. If you are comparable DOI: 10.1213/ANE.0000000000000861 to their patients and get exactly the same treatment, it is Number 4 www.anesthesia-analgesia.org 1043 ڇ Volume 121 ڇ October 2015 Copyright © 2015 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited. E REVIEW ARTICLE reasonable to expect to have about a 50-50 chance of living reintubations are also rare—too rare, in fact—to practically more or less than 37 months. evaluate in prospective trials. The trouble is that this result, although useful for con- An alternative approach is to fnd patients who required sidering the prognosis of an individual already committed reintubation in the postanesthesia care unit and compare to the particular treatment, offers no comparative context. them to a similar group of patients who did not. Investigators Median survival for comparable patients is not all that we can then look backward in time and determine, for exam- want to know; what we really need to understand is whether ple, which patients in each group had their neuromuscular this survival (or any other outcome) is better or worse with block reversed. If patients who required reintubation were this treatment than with alternatives, and that is where the signifcantly less likely to have been given reversal agents, logic gets tricky. The danger is that in assessing alternative one can conclude that there is an association between inad- treatment plans, the results of a case series of a new treat- equate block reversal and emergent reintubation. The basic ment are almost always implicitly or explicitly compared approach to such case-control studies is shown in Figure 1. with previous results, that is, to a “historical control.” For case-control studies to be valid, the case and control Historically controlled studies tend to falsely generate groups must be chosen or statistically adjusted to be compa- a conclusion that new treatment or local management is rable with respect to potential confounding factors, and the superior because the comparative effects of the treatment assessment of exposures and potential confounding factors tend to get mixed up with, or confounded by, other time- must be equally complete and accurate for both. A danger dependent changes. For instance, recent patients may have with clinical records is that important potential confound- been diagnosed earlier in their disease courses than his- ers may not have been evaluated or may have been inaccu- torical patients because of the improvement in diagnostic rately recorded. They may also be nonrandomly erroneous: imaging or other technology. Patients diagnosed earlier— for example, patients who have complications may have a the recent ones—would thus be expected to survive lon- more complete list of preexisting conditions. A further dan- ger from the time of diagnoses whether or not the new ger is that important confounding factors may be unknown treatment they receive is an improvement. This problem and thus not even considered by investigators. is known as “lead time” bias in the context of studies of But because investigators must look back in time— medical screening. Because there is no way to recover when sometimes quite far back—it is diffcult to determine the diagnoses would have occurred had the historical reference extent to which the groups might meaningfully differ. subjects been seen under present conditions, it is diffcult Equivalent exposure assessment for both groups may also or impossible to retroactively correct for this problem. be hard to ensure. For example, data about cases often must Alternatively, therapy for some disease-related complica- be obtained directly from patients or their families, whose tions may have improved over time. Improved treatment memories may be stimulated by the symptoms, diagnostic of these complications, rather than the new therapy, may processes, and concerns about the disease. In contrast, the have improved
Recommended publications
  • Levels of Evidence Table
    Levels of Evidence All clinically related articles will require a Level-of-Evidence rating for classifying study quality. The Journal has five levels of evidence for each of four different study types; therapeutic, prognostic, diagnostic and cost effectiveness studies. Authors must classify the type of study and provide a level - of- evidence rating for all clinically oriented manuscripts. The level-of evidence rating will be reviewed by our editorial staff and their decision will be final. The following tables and types of studies will assist the author in providing the appropriate level-of- evidence. Type Treatment Study Prognosis Study Study of Diagnostic Test Cost Effectiveness of Study Study LEVEL Randomized High-quality Testing previously Reasonable I controlled trials prospective developed costs and with adequate cohort study diagnostic criteria alternatives used statistical power with > 80% in a consecutive in study with to detect follow-up, and series of patients values obtained differences all patients and a universally from many (narrow enrolled at same applied “gold” standard studies, study confidence time point in used multi-way intervals) and disease sensitivity follow up >80% analysis LEVEL Randomized trials Prospective cohort Development of Reasonable costs and II (follow up <80%, study (<80% follow- diagnostic criteria in a alternatives used in Improper up, patients enrolled consecutive series of study with values Randomization at different time patients and a obtained from limited Techniques) points in disease) universally
    [Show full text]
  • TUTORIAL in BIOSTATISTICS: the Self-Controlled Case Series Method
    STATISTICS IN MEDICINE Statist. Med. 2005; 0:1–31 Prepared using simauth.cls [Version: 2002/09/18 v1.11] TUTORIAL IN BIOSTATISTICS: The self-controlled case series method Heather J. Whitaker1, C. Paddy Farrington1, Bart Spiessens2 and Patrick Musonda1 1 Department of Statistics, The Open University, Milton Keynes, MK7 6AA, UK. 2 GlaxoSmithKline Biologicals, Rue de l’Institut 89, B-1330 Rixensart, Belgium. SUMMARY The self-controlled case series method was developed to investigate associations between acute outcomes and transient exposures, using only data on cases, that is, on individuals who have experienced the outcome of interest. Inference is within individuals, and hence fixed covariates effects are implicitly controlled for within a proportional incidence framework. We describe the origins, assumptions, limitations, and uses of the method. The rationale for the model and the derivation of the likelihood are explained in detail using a worked example on vaccine safety. Code for fitting the model in the statistical package STATA is described. Two further vaccine safety data sets are used to illustrate a range of modelling issues and extensions of the basic model. Some brief pointers on the design of case series studies are provided. The data sets, STATA code, and further implementation details in SAS, GENSTAT and GLIM are available from an associated website. key words: case series; conditional likelihood; control; epidemiology; modelling; proportional incidence Copyright c 2005 John Wiley & Sons, Ltd. 1. Introduction The self-controlled case series method, or case series method for short, provides an alternative to more established cohort or case-control methods for investigating the association between a time-varying exposure and an outcome event.
    [Show full text]
  • Supplementary File
    Supplementary file Table S1. Characteristics of studies included in the systematic review. Authors, reference Type of article Number of patients Type of stroke Valderrama [1] case report 1 AIS Oxley [2] case series 5 AIS Morassi [3] case series 6 AIS (n = 4), HS (n = 2) Tunc [4] case series 4 AIS Avula [5] case series 4 AIS (n = 3), TIA (n = 1) Oliver [6] case report 1 AIS Beyrouti [7] case series 6 AIS Al Saiegh [8] case series 2 AIS (n = 1), SAH (n = 1) Gunasekaran [9] case report 1 AIS Goldberg [10] case report 1 AIS Viguier [11] case report 1 AIS Escalard [12] case series/ case control 10 AIS Wang [13] case series 5 AIS Fara [14] case series 3 AIS Moshayedi [15] case report 1 AIS Deliwala [16] case report 1 AIS Sharafi-Razavi [17] case report 1 HS retrospective cohort study (case Jain [18] 35 AIS (n = 26) HS (n = 9) control) retrospective cohort study (case Yaghi [19] 32 AIS control) AIS (n = 35), TIA (n = 5), HS Benussi [20] retrospective cohort study 43 (n = 3) Rudilosso [21] case report 1 AIS Lodigiani [22] retrospective cohort study 9 AIS Malentacchi [23] case report 1 AIS J. Clin. Med. 2020, 9, x; doi: FOR PEER REVIEW www.mdpi.com/journal/jcm J. Clin. Med. 2020, 9, x FOR PEER REVIEW 2 of 8 retrospective cohort study/case Scullen [24] 2 HS + AIS (n = 1), AIS (n = 1) series retrospective cohort study/ case AIS (n = 17), ST (n = 2), HS Sweid [25] 22 series (n = 3) AIS – acute ischemic stroke; HS – haemorrhagic stroke; SAH – subarachnoid haemorrhage; ST – sinus thrombosis; TIA-transient ischemic attack.
    [Show full text]
  • Quasi-Experimental Studies in the Fields of Infection Control and Antibiotic Resistance, Ten Years Later: a Systematic Review
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Infect Control Manuscript Author Hosp Epidemiol Manuscript Author . Author manuscript; available in PMC 2019 November 12. Published in final edited form as: Infect Control Hosp Epidemiol. 2018 February ; 39(2): 170–176. doi:10.1017/ice.2017.296. Quasi-experimental Studies in the Fields of Infection Control and Antibiotic Resistance, Ten Years Later: A Systematic Review Rotana Alsaggaf, MS, Lyndsay M. O’Hara, PhD, MPH, Kristen A. Stafford, PhD, MPH, Surbhi Leekha, MBBS, MPH, Anthony D. Harris, MD, MPH, CDC Prevention Epicenters Program Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland. Abstract OBJECTIVE.—A systematic review of quasi-experimental studies in the field of infectious diseases was published in 2005. The aim of this study was to assess improvements in the design and reporting of quasi-experiments 10 years after the initial review. We also aimed to report the statistical methods used to analyze quasi-experimental data. DESIGN.—Systematic review of articles published from January 1, 2013, to December 31, 2014, in 4 major infectious disease journals. METHODS.—Quasi-experimental studies focused on infection control and antibiotic resistance were identified and classified based on 4 criteria: (1) type of quasi-experimental design used, (2) justification of the use of the design, (3) use of correct nomenclature to describe the design, and (4) statistical methods used. RESULTS.—Of 2,600 articles, 173 (7%) featured a quasi-experimental design, compared to 73 of 2,320 articles (3%) in the previous review (P<.01). Moreover, 21 articles (12%) utilized a study design with a control group; 6 (3.5%) justified the use of a quasi-experimental design; and 68 (39%) identified their design using the correct nomenclature.
    [Show full text]
  • Case Series: COVID-19 Infection Causing New-Onset Diabetes Mellitus?
    Endocrinology & Metabolism International Journal Case Series Open Access Case series: COVID-19 infection causing new-onset diabetes mellitus? Abstract Volume 9 Issue 1 - 2021 Objectives: This paper seeks to explore the hypothesis of the potential diabetogenic effect 1 2 of SARS-COV-2 (Severe Acute respiratory syndrome coronavirus). Rujuta Katkar, Narasa Raju Madam 1Consultant Endocrinologist at Yuma Regional Medical Center, Case series presentation: We present a case series of observation among 8 patients of age USA 2 group ranging from 34 to 74 years with a BMI range of 26.61 to 53.21 Kilogram/square Hospitalist at Yuma Regional Medical Center, USA meters that developed new-onset diabetes after COVID-19 infection. Correspondence: Rujuta Katkar, MD, Consultant Severe Acute Respiratory Syndrome Coronavirus (SARS-COV-2), commonly known as Endocrinologist at Yuma Regional Medical Center, 2851 S Coronavirus or COVID-19(Coronavirus infectious disease), gains entry into the cells by Avenue B, Bldg.20, Yuma, AZ-85364, USA, Tel 2034359976, binding to the Angiotensin-converting enzyme-2(ACE-2) receptors located in essential Email metabolic tissues including the pancreas, adipose tissue, small intestine, and kidneys. Received: March 25, 2021 | Published: April 02, 2021 The evidence reviewed from the scientific literature describes how ACE 2 receptors play a role in the pathogenesis of diabetes and the plausible interaction of SARS-COV-2 with ACE 2 receptors in metabolic organs and tissues. Conclusion: The 8 patients without a past medical history of diabetes admitted with COVID-19 infection developed new-onset diabetes mellitus due to plausible interaction of SARS-COV-2 with ACE 2 receptors.
    [Show full text]
  • NIH Definition of a Clinical Trial
    UNIVERSITY OF CALIFORNIA, SAN DIEGO HUMAN RESEARCH PROTECTIONS PROGRAM NIH Definition of a Clinical Trial The NIH has recently changed their definition of clinical trial. This Fact Sheet provides information regarding this change and what it means to investigators. NIH guidelines include the following: “Correctly identifying whether a study is considered to by NIH to be a clinical trial is crucial to how [the investigator] will: Select the right NIH funding opportunity announcement for [the investigator’s] research…Write the research strategy and human subjects section of the [investigator’s] grant application and contact proposal…Comply with appropriate policies and regulations, including registration and reporting in ClinicalTrials.gov.” NIH defines a clinical trial as “A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.” NIH notes, “The term “prospectively assigned” refers to a pre-defined process (e.g., randomization) specified in an approved protocol that stipulates the assignment of research subjects (individually or in clusters) to one or more arms (e.g., intervention, placebo, or other control) of a clinical trial. And, “An ‘intervention’ is defined as a manipulation of the subject or subject’s environment for the purpose of modifying one or more health-related biomedical or behavioral processes and/or endpoints. Examples include:
    [Show full text]
  • The Value of Case Reports in Systematic Reviews from Rare Diseases
    International Journal of Environmental Research and Public Health Article The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II) Miguel Sampayo-Cordero 1,2,*, Bernat Miguel-Huguet 3, Andrea Malfettone 1,2, José Manuel Pérez-García 1,2,4, Antonio Llombart-Cussac 1,2,5, Javier Cortés 1,2,4,6, Almudena Pardo 7 and Jordi Pérez-López 8 1 Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ 07450, USA; [email protected] (A.M.); [email protected] (J.M.P.-G.); [email protected] (A.L.-C.); [email protected] (J.C.) 2 Medica Scientia Innovation Research (MedSIR), 08018 Barcelona, Spain 3 Department of Surgery, Hospital de Bellvitge, L’Hospitalet de Llobregat, 08907 Barcelona, Spain; [email protected] 4 Institute of Breast Cancer, Quiron Group, 08023 Barcelona, Spain 5 Hospital Arnau de Vilanova, Universidad Católica de Valencia “San Vicente Mártir”, 46015 Valencia, Spain 6 Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain 7 Albiotech Consultores y Redacción Científica S.L., 28035 Madrid, Spain; [email protected] 8 Department of Internal Medicine, Hospital Vall d’Hebron, 08035 Barcelona, Spain; [email protected] * Correspondence: [email protected] Received: 3 August 2020; Accepted: 7 September 2020; Published: 10 September 2020 Abstract: Background: Case reports are usually excluded from systematic reviews. Patients with rare diseases are more dependent on novel individualized strategies than patients with common diseases. We reviewed and summarized the novelties reported by case reports in mucopolysaccharidosis type II (MPS-II) patients treated with enzyme replacement therapy (ERT).
    [Show full text]
  • E 8 General Considerations for Clinical Trials
    European Medicines Agency March 1998 CPMP/ICH/291/95 ICH Topic E 8 General Considerations for Clinical Trials Step 5 NOTE FOR GUIDANCE ON GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (CPMP/ICH/291/95) TRANSMISSION TO CPMP November 1996 TRANSMISSION TO INTERESTED PARTIES November 1996 DEADLINE FOR COMMENTS May 1997 FINAL APPROVAL BY CPMP September 1997 DATE FOR COMING INTO OPERATION March 1998 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 85 75 Fax (44-20) 75 23 70 40 E-mail: [email protected] http://www.emea.eu.int EMEA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged GENERAL CONSIDERATIONS FOR CLINICAL TRIALS ICH Harmonised Tripartite Guideline Table of Contents 1. OBJECTIVES OF THIS DOCUMENT.............................................................................3 2. GENERAL PRINCIPLES...................................................................................................3 2.1 Protection of clinical trial subjects.............................................................................3 2.2 Scientific approach in design and analysis.................................................................3 3. DEVELOPMENT METHODOLOGY...............................................................................6 3.1 Considerations for the Development Plan..................................................................6 3.1.1 Non-Clinical Studies ........................................................................................6
    [Show full text]
  • Double Blind Trials Workshop
    Double Blind Trials Workshop Introduction These activities demonstrate how double blind trials are run, explaining what a placebo is and how the placebo effect works, how bias is removed as far as possible and how participants and trial medicines are randomised. Curriculum Links KS3: Science SQA Access, Intermediate and KS4: Biology Higher: Biology Keywords Double-blind trials randomisation observer bias clinical trials placebo effect designing a fair trial placebo Contents Activities Materials Activity 1 Placebo Effect Activity Activity 2 Observer Bias Activity 3 Double Blind Trial Role Cards for the Double Blind Trial Activity Testing Layout Background Information Medicines undergo a number of trials before they are declared fit for use (see classroom activity on Clinical Research for details). In the trial in the second activity, pupils compare two potential new sunscreens. This type of trial is done with healthy volunteers to see if the there are any side effects and to provide data to suggest the dosage needed. If there were no current best treatment then this sort of trial would also be done with patients to test for the effectiveness of the new medicine. How do scientists make sure that medicines are tested fairly? One thing they need to do is to find out if their tests are free of bias. Are the medicines really working, or do they just appear to be working? One difficulty in designing fair tests for medicines is the placebo effect. When patients are prescribed a treatment, especially by a doctor or expert they trust, the patient’s own belief in the treatment can cause the patient to produce a response.
    [Show full text]
  • Download, And
    medRxiv preprint doi: https://doi.org/10.1101/19002121; this version posted July 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Evaluation of Indicators of Reproducibility and Transparency in Published Cardiology Literature Short Title: Anderson et al.; Indicators of Reproducibility in Cardiology J. Michael Anderson, B.S.1, Bryan Wright, B.G.S.1, Daniel Tritz, B.S.1, Jarryd Horn, B.S.1, Ian Parker, D.O.2, Daniel Bergeron, D.O.2, Sharolyn Cook, D.O.2, Matt Vassar, PhD1 1. Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA 2. Oklahoma State University Medical Center - Department of Cardiology, Tulsa, Oklahoma, USA Corresponding Author: Mr. J. Michael Anderson, Oklahoma State University Center for Health Sciences, 1111 W 17th St Tulsa, OK 74107, United States; Fax: 918-561-8428; Telephone: 918-521-8774; Email: [email protected] Word Count: 7041 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/19002121; this version posted July 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract: Background The extent of reproducibility in cardiology research remains unclear. Therefore, our main objective was to determine the quality of research published in cardiology journals using eight indicators of reproducibility.
    [Show full text]
  • Top Ten Cool Things About 250B Exam 1
    Cohort Studies Madhukar Pai, MD, PhD McGill University Montreal 1 Cohort: origins of the word http://www.caerleon.net/ 2 Introduction • Measurement of the occurrence of events over time is a central goal of epidemiologic research • Regardless of any particular study design or hypothesis, interest is ultimately in the disease or outcome-causing properties of factors that are antecedent to the disease or outcome. • All study designs (including case control and cross- sectional studies) are played out in some populations over time (either well defined cohorts or not) – They differ in how they acknowledge time and how they sample exposed and non-exposed as these groups develop disease over time 3 All the action happens within a “sea of person-time” in which events occur 4 Morgenstern IJE 1980 Cohort studies Intuitive approach to studying disease incidence and risk factors: 1. Start with a population at risk 2. Measure exposures and covariates at baseline 3. Follow-up the cohort over time with a) Surveillance for events or b) re-examination 4. Keep track of attrition, withdrawals, drop-outs and competing risks 5. For covariates that change over time, measure them again during follow up 6. Compare event rates in people with and without exposures of interest - Incidence Density Ratio (IDR) is the most natural and appropriate measure of effect - Adjust for confounders and compute adjusted IDR - Look for effect measure modification, if appropriate 5 Cohort studies • Can be large or small • Can be long or short duration • Can be simple or elaborate • Can look at multiple exposures and multiple outcomes • Can look at changes in exposures over time • For rare outcomes need many people and/or lengthy follow- up • Are usually very expensive because of the numbers and follow-up requirements • But once a cohort is established, can sustain research productivity for a long, long time! 6 Cohort: keeping track of people 7 Szklo & Nieto.
    [Show full text]
  • Observational Studies and Bias in Epidemiology
    The Young Epidemiology Scholars Program (YES) is supported by The Robert Wood Johnson Foundation and administered by the College Board. Observational Studies and Bias in Epidemiology Manuel Bayona Department of Epidemiology School of Public Health University of North Texas Fort Worth, Texas and Chris Olsen Mathematics Department George Washington High School Cedar Rapids, Iowa Observational Studies and Bias in Epidemiology Contents Lesson Plan . 3 The Logic of Inference in Science . 8 The Logic of Observational Studies and the Problem of Bias . 15 Characteristics of the Relative Risk When Random Sampling . and Not . 19 Types of Bias . 20 Selection Bias . 21 Information Bias . 23 Conclusion . 24 Take-Home, Open-Book Quiz (Student Version) . 25 Take-Home, Open-Book Quiz (Teacher’s Answer Key) . 27 In-Class Exercise (Student Version) . 30 In-Class Exercise (Teacher’s Answer Key) . 32 Bias in Epidemiologic Research (Examination) (Student Version) . 33 Bias in Epidemiologic Research (Examination with Answers) (Teacher’s Answer Key) . 35 Copyright © 2004 by College Entrance Examination Board. All rights reserved. College Board, SAT and the acorn logo are registered trademarks of the College Entrance Examination Board. Other products and services may be trademarks of their respective owners. Visit College Board on the Web: www.collegeboard.com. Copyright © 2004. All rights reserved. 2 Observational Studies and Bias in Epidemiology Lesson Plan TITLE: Observational Studies and Bias in Epidemiology SUBJECT AREA: Biology, mathematics, statistics, environmental and health sciences GOAL: To identify and appreciate the effects of bias in epidemiologic research OBJECTIVES: 1. Introduce students to the principles and methods for interpreting the results of epidemio- logic research and bias 2.
    [Show full text]